Search alternatives:
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
19 a » 19 _ (Expand Search), 19 p (Expand Search), 1 a (Expand Search)
Showing 61 - 80 results of 50,612 for search '(( 5 ((((ng decrease) OR (nn decrease))) OR (mean decrease)) ) OR ( 19 a decrease ))', query time: 0.99s Refine Results
  1. 61
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 62
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 63
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 64
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 65
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 66
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 67
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 68
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 69
    CD11b and TLR-5 expression are decreased on CF macrophage membrane.

    CD11b and TLR-5 expression are decreased on CF macrophage membrane. by Karin Simonin-Le Jeune (464354)

    Published 2013
    Save to List
    Saved in:
  10. 70
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 71
    5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial

    5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial by Moniyka Sachar (9399032)

    Published 2020
    Save to List
    Saved in:
  12. 72
    Evaluation of <i>in vitro</i> activity of LNP-siRNA on LX-2 cells stimulated by 2 ng/mL of TGF-β.

    Evaluation of <i>in vitro</i> activity of LNP-siRNA on LX-2 cells stimulated by 2 ng/mL of TGF-β. by Ying-Chou Chen (263436)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 73
    Likelihood of a decrease in runoff (a), an increase in runoff (b) and a severe change in ecosystems (c) for selected Δ<em>T</em><sub>g</sub> levels

    Likelihood of a decrease in runoff (a), an increase in runoff (b) and a severe change in ecosystems (c) for selected Δ<em>T</em><sub>g</sub> levels by Dieter Gerten (557088)

    Published 2013
    “…Projections are based on a new, consistent set of 152 climate scenarios (eight Δ<em>T</em><sub>g</sub> trajectories reaching 1.5–5 ° C above pre-industrial levels by 2100, each scaled with spatial patterns from 19 general circulation models). …”
    Save to List
    Saved in:
  14. 74
    Rapamycin decreases phosphorylation of S6.

    Rapamycin decreases phosphorylation of S6. by Adam L. Hartman (308128)

    Published 2013
    Save to List
    Saved in:
  15. 75
    Virion production is significantly decreased by rapamycin treatment.

    Virion production is significantly decreased by rapamycin treatment. by Lisa A. Nichols (357612)

    Published 2013
    Save to List
    Saved in:
  16. 76
    HIV Tropism and Decreased Risk of Breast Cancer

    HIV Tropism and Decreased Risk of Breast Cancer by Nancy A. Hessol (191696)

    Published 2010
    Save to List
    Saved in:
  17. 77
    A T-test mean comparison of pre and post COVID-19 differences for selected variables.

    A T-test mean comparison of pre and post COVID-19 differences for selected variables. by Beshir Bedru Nasir (8218863)

    Published 2024
    Save to List
    Saved in:
  18. 78
    DGAT-1 Inhibitor A922500 decreases the pro-inflammatory profile and cell death induced by SARS-CoV-2 infection and reduces the viral load in human monocyte.

    DGAT-1 Inhibitor A922500 decreases the pro-inflammatory profile and cell death induced by SARS-CoV-2 infection and reduces the viral load in human monocyte. by Suelen Silva Gomes Dias (9928813)

    Published 2020
    Save to List
    Saved in:
  19. 79
    Suppression of the growth defects in flippase mutants by decreased synthesis of PI.

    Suppression of the growth defects in flippase mutants by decreased synthesis of PI. by Kanako Yamagami (703555)

    Published 2015
    Save to List
    Saved in:
  20. 80
    Neto1 Loss of Function Decreases tbLTP in CA1 Hippocampus

    Neto1 Loss of Function Decreases tbLTP in CA1 Hippocampus by David Ng (266907)

    Published 2009
    Save to List
    Saved in:

Search Tools: